Price
$8.38
Decreased by -12.53%
Dollar Volume
50.37 M
ADR%
11.46
Earnings Report Date (estimate)
Feb 7, 23 (-0.16)
Market Cap.
653.32 M
Shares Float
75.61 M
Shares Outstanding
77.96 M
Beta
0.71
Price / Earnings
-14.47
BPR
66.11
20D Range
8.29 15.24
50D Range
8.29 15.24
200D Range
7.13 15.24
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 28, 22 -0.18
Decreased by -20.00%
-0.16
Decreased by -12.50%
Aug 9, 22 -0.16
Decreased by -14.29%
-0.15
Decreased by -6.67%
May 10, 22 -0.14
Decreased by -16.67%
-0.17
Increased by +17.65%
Feb 9, 22 -0.14
Decreased by -16.67%
-0.15
Increased by +6.67%
Nov 24, 21 -0.15
Decreased by -50.00%
-0.15
Aug 12, 21 -0.14
Decreased by -27.27%
-0.13
Decreased by -7.69%
May 13, 21 -0.12
Increased by 0.00%
-0.14
Increased by +14.29%
Feb 11, 21 -0.12
Increased by 0.00%
-0.11
Decreased by -9.09%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-14.29 M
Decreased by -21.95%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-12.37 M
Decreased by -21.48%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-10.44 M
Decreased by -27.99%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-10.88 M
Decreased by -38.54%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-11.72 M
Decreased by -96.44%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-10.18 M
Decreased by -56.94%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-8.16 M
Decreased by -12.69%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-7.86 M
Decreased by -19.16%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.